Living with ADHD while going through menopause can be challenging, but there are ways to manage both.

What do ADHD and menopause have in common other than mood changes and inattention?

Though some symptoms are observable on the outside, folks around you may not understand even half of what youre handling internally, let alone that youre managing both at the same time.

Living with attention deficit hyperactivity disorder (ADHD) comes with its own challenges. And if youre going through perimenopause or menopause, you may face more difficulties.

ADHD is a neurocognitive disorder that has three presentations:

People can receive a diagnosis early in childhood as well as late in life.

Dr. Ellen Littman, a clinical psychologist in New York state, explains that estrogen has powerful effects on brain chemistry throughout your lifetime.

Menopause is among the top biggest events to change estrogen in your body, among starting your period and becoming pregnant.

Estrogen is considered neuroprotective, in that high levels increase the availability of neurotransmitters (brain messengers) like dopamine and serotonin, which enhance cognition, mood, sleep, verbal memory, and even ADHD symptoms, Littman says, who is publishing an upcoming review article about the female hormonal effects on ADHD.

However, your levels of estrogen decline beginning in perimenopause and are spent during menopause.

While people face some symptoms off and on during menopause, Littman says those who also have ADHD experience intensified symptoms.

By understanding the relationship between menopause and increased ADHD symptoms, they are less likely to be ambushed by the amplified difficulties they experience, she says.

Both ADHD and menopause are known for patternless shifts in brain activity and hormone changes.

So, you might begin to see how overlapping symptoms happening concurrently or one after the other can worsen the experience of both conditions and make them difficult to manage.

A 2016 study even looks at the effectiveness of using ADHD medication to treat people experiencing executive function issues during menopause.

While going through menopause when you have ADHD can feel overwhelming, there are ways you can manage both conditions.

Finding a psychiatrist whos well versed and experienced in treating ADHD in people going through menopause can help you get the care you deserve.

While it might not be easy to find a psychiatrist with experience in this area, start by asking your current mental health professional or gynecologist for recommendations.

If you cant find a psychiatrist whos familiar with research demonstrating hormone involvement in ADHD symptoms, Littman suggests sharing information or articles (like this one) with them.

If you feel that your credibility is being questioned, its important to feel entitled to finding the clinician who best fits your needs, she says.

Littman suggests finding a gynecologist whos experienced in treating people going through menopause, and who will also work with the doctor who treats your ADHD.

Since women now spend about a third of their lives in menopause, it is critical to find a treatment regimen tailored to your specific needs, she says.

According to a 2019 survey of postgraduate resident trainees in family medicine, internal medicine, and obstetrics and gynecology in U.S. residency programs, only 6.8% of them reported feeling just adequately prepared to manage women experiencing menopause.

No one clinician is knowledgeable about all aspects of each individual experience, but Littman says finding doctors who will collaborate and communicate with your gynecologist can help tailor treatment.

For instance, if your ADHD medications need adjusting, as well as your decreasing estrogen levels, having both your gynecologist and doctor who treats your ADHD collaborate could help.

While pharmacologists often adjust the dosage to meet the new challenges, increased estrogen could address both menopausal and ADHD symptoms. Bioidentical hormone replacement therapy (HRT) is one route to increased estrogen for many women, Littman says.

Although your doctors may be hesitant to communicate with each other, being assertive and informing them of your conditions, as well as bringing information from each doctor to your appointments, can help ensure theyre in tune with whats going on with your body.

While theres a wide range of menopausal symptoms that occur on a continuum, Littman points out that ADHD can worsen symptoms like impaired cognition and mood.

In fact, a 2019 research paper suggests that ADHD symptoms, and even concurrent symptoms from other conditions, are also vulnerable to the hormonal changes experienced during menopause, says Littman.

Both conditions can muddle with your executive functions, a clinical term for your:

If you find that these areas of your life are becoming more difficult to manage, coming up with a plan to help navigate them can make your days easier.

For instance, if keeping and organizing appointments and commitments is difficult, setting an email calendar reminder so you get notifications on your phone, tablet, and desktop can help you stay on track.

If self-monitoring is a blind spot as of late, you could try leaning on your inner circle to gently give you a signal if agitation or strong emotions are coming off more than intended.

You might also look into present moment awareness to reconnect with mindfulness and strengthen your self-awareness.

In addition to seeing a professional, Littman suggests pursuing your own psychoeducation. Consider bookmarking the following resources:

The more you can understand about the relationship between your [brains response to ADHD] and your body in menopause, the more you can be an active participant in your treatment. And the more your support network understands about your challenges, the more supportive and compassionate they can be, Littman says.

While managing your ADHD while going through menopause can be challenging at times, there are ways to make the process easier.

Littman says that on the clinical front, new research brings hope for better treatments ahead.

Were on the brink of an exciting new understanding of the experience of women with ADHD, she says. As new studies continue to implicate the powerful role of hormones in womens experience of ADHD, the potential for more comprehensive and successful treatments may be on the horizon.

You can stay tuned for Littman and teams upcoming study on ADHD and estrogen, titled: ADHD in Females Across the Lifespan and the Role of Estrogen. It publishes August 2021 in The ADHD Report.

Original post:
Tips to Manage when You're in Menopause with ADHD - PsychCentral.com

Recommendation and review posted by Bethany Smith

Local health-care providers are being asked to fill out a survey to help make it easier for people who are transgender to access care in Hamilton.

The Hamilton Trans Health Coalition is calling on primary care providers to explain what barriers they face in providing gender-affirming care for patients who are trans.

Gender-affirming care includes things that are related to transitioning, like HRT (hormone replacement therapy) or surgery, but also includes doctors recognizing their patients pronouns and chosen names, and not making assumptions about their sexual history or sexual orientation.

Cole Gately, chair of the coalition, said the goal of the survey is to determine what kind of barriers and motivators are impacting Hamiltons health-care providers when they have a patient who is trans.

Story continues below advertisement

We just want to know what are the barriers, whats getting in the way? Why arent you doing it and how can we help? There are lots of resources out there. Maybe youre not aware of them.

Since introducing a project co-ordinator earlier this year, the coalition has heard from some doctors, but its also heard from many trans Hamiltonians who are travelling outside of the city to get basic health care that their own doctors are capable of providing.

Trending Stories

Gately said some people are being told by their doctors to seek out specific care on their own and then theyll write a referral, but he said that burden shouldnt be on the patient if providing that care is well within the doctors own abilities.

Story continues below advertisement

What I said to somebody yesterday was, imagine if you broke your wrist and you went into the doctor and the doctor said, Well, you find an orthopedic surgeon and then Ill make the referral. That doesnt happen. The doctor finds the orthopedic surgeon for you and makes the referral because the doctor is the expert.

The survey is open until July 28 and the coalition is urging any and all primary care providers in Hamilton including family doctors, registered nurses, nurse practitioners and physician assistants to fill it out.

2021 Global News, a division of Corus Entertainment Inc.

Link:
Primary care providers called on to respond to survey to improve trans health care in Hamilton - Global News

Recommendation and review posted by Bethany Smith

Arianna Sholes-Douglas remembers the moment her body was in the grips of perimenopause though she didnt recognize it for what it was at the time, despite being an OB-GYN and integrative health physician focusing on womens health. Sholes-Douglas was performing a C-section, a surgery she estimates she had done over a thousand times, and her brain just blanked.

I had a total brain freeze. I couldnt remember what to do, she recalled. It was very scary, and I didnt know who to talk to or what to do.

At first, she worried it was early-onset Alzheimers. But the big changes shed been experiencing in cognitive function were hormonal. She was going through perimenopause, the transitional period before menopause when a womans body starts making less estrogen until eventually her ovaries stop releasing eggs.

And shes not alone about being in the dark. Many Gen X women and cusp millennials who are at the age range when perimenopause has begun or could soon start have far too little support and information.

We havent been educated. Patients havent been educated. Doctors havent been educated. There really hasnt been a resource thats been reliable for women, so they are caught off-guard, said Sholes-Douglas, who went on to write the book The Menopause Myth: What Your Mother, Doctor, and Friends Havent Told You About Life After 35.

Because in their minds, theyre thinking menopause is an old lady issue, she added. They think its only relevant when they stop having a period.

But thats not true. So here are three important things Xennial women should know about perimenopause:

It can start in your 30s or 40s.

There arent lines around when perimenopause begins, in part because it varies by individual and also because the types of symptoms are so broad. The term perimenopause really just means around menopause.

Its also a stretch of time that can drag on for a while. Many women start to experience symptoms five or even 10 years before they stop having a period (though the average is about four years). And given that full menopause can happen when women are in their 40s or 50s, perimenopause can begin when theyre in their early 40s or even mid-30s.

Since 5% to 7% of women are fully menopausal by age 45 (theyve gone that magical full year without a period), they could be experiencing these symptoms at age 40, not thinking a thing about menopause because these symptoms can be very vague and dont come with a big sign You are entering perimenopause, said Mary Jane Minkin, an OB-GYN with Yale University and founder of the informational website Madame Ovary.

Youre still able to get pregnant during perimenopause.

If youre a woman in your 30s or 40s who is planning to have children (and many women are) and youre fretting that you might instead enter perimenopause, dont freak out. Its very much still possible for women to get pregnant during this phase, though its definitely worth bringing up with your doctor if you have concerns.

The symptoms go way beyond hot flashes.

When most people think menopause, they think of hot flashes. And many (if not most) women getting closer to menopause will experience hot flashes, or brief feelings of being overheated, at some point ranging from pretty mild to really severe.

But there are so many other symptoms that can come along with perimenopause, including missed periods or periods that are heavier or lighter than usual, mood swings, changes in cholesterol levels and bone density, urinary incontinence and cognitive fuzziness.

Many [women] get disrupted sleep usually falling asleep quickly as they are exhausted, but are then up at 1 a.m., sometimes with a hot flash, sometimes without. They may have headaches, they may be achy, they may have some vaginal dryness or urinary leakage (although that usually comes later), Minkin said.

Perimenopause can affect your sexual health and well-being, as well. The sexual aspect part of perimenopause is something I deal with a lot, Sholes-Douglas said. Women are very much caught off-guard when they experience a decline in libido, vaginal pain, vaginal dryness and they dont know why.

But while the possible symptoms associated with perimenopause are wide-ranging, they all really come back to the hormonal changes women go through in the run-up to menopause, as estrogen and progesterone levels fall or rise and fall in uneven spikes.

The Good Brigade via Getty Images

Finding adequate care and support can still be difficult.

Though theres far more information available to women and health care providers now than had been the case a few decades ago, and many active support communities have flourished, perimenopause is still something women arent adequately educated about, according to experts.

Minkin said Gen X women are probably slightly better prepared, but not dramatically so. Sholes-Douglas was more emphatic: Most women are just not prepared.

There are a few reasons for this, one of which is that there simply isnt a test doctors can perform to see if women have entered perimenopause.

Hormone levels may not show much, Minkin said. For example, a doctor might do an estradiol test to check your estrogen levels, but since normal levels during a menstrual cycle range wildly (from 45 to 350 picograms per milliliter), its hard to know where your level should be.

Lets say we draw a blood level of 50. Well, is that normal? It may be. But if your level should be 300, thats low, Minkin explained.

Its a tough diagnosis to make at the time, she added. When the patient goes that year without the period, you can then say, Well, hey that was all perimenopausal!

On top of which there is a lack of consensus about how to treat symptoms of perimenopause even if it is clear thats the issue. Hormone therapy, which involves taking supplemental hormones, is one option, but some past studies have indicated it can come with other health risks. Some doctors might recommend lifestyle changes to help manage symptoms; in other cases, women might take medications to more directly address such symptoms as vaginal dryness or mental health changes.

Unfortunately, a lot of this ends up falling on women. They end up needing to connect the dots in their own symptoms and find health care providers who have experience dealing with perimenopause. Which is why it is so important for Xennial women to be aware of whats happening in their bodies now, or what lies just ahead.

Ive had countless patients tell me they went to the doctor and told them they suspected they were perimenopausal, and the doctor said: Oh, youre too young for that. Youre too young for that, Sholes-Douglas said.

You should not assume that your doctor is going to know more about this than you do, she added. On some level, obviously they will. But dont underestimate the power you have.

More:
Perimenopause: The Women's Health Issue No One's Talking About Enough - HuffPost

Recommendation and review posted by Bethany Smith

I am a 77-year-old woman. I am 5 feet, 2 inches tall and weigh 107 pounds. I take no medication. When I went to the doctor last week, he found that my alkaline phosphatase was 176, my ALT 10, and my AST 11. He told me I had fatty liver and to get a scan, but I had no way to get to the place to have it done. He did not say anything else about it. I have no symptoms. Does this sound like fatty liver to you? I did not really like my doctor, but with my insurance it is hard to change doctors. If I do have fatty liver, is there anything I can do for it?

Fatty liver is an increasingly common problem. Risk factors include being overweight and having diabetes, high blood pressure and abnormal blood cholesterol levels.

Alcohol use is also a cause of fatty liver, and all people with fatty liver are strongly recommended to abstain from alcohol entirely. The primary treatment is diet and weight loss.

It sounds like there was some missed communication between you and your doctor. Fatty liver is a possibility; however, it does not seem likely to me, as you have not identified any of the risk factors, and you are certainly not overweight if anything, you are a bit underweight.

Further, although the alkaline phosphatase can be elevated in fatty liver yours is just a bit high it is more common for AST and ALT to be elevated, which yours are not.

An ultrasound scan is a good, but not definitive, way of looking for fatty liver. A liver biopsy is still the definitive test, but its often not done in people whose history, physical exam and ultrasound are all suggestive.

A slightly abnormal alkaline phosphatase does not necessarily mean you have a liver problem. Bone issues fractures, Pagets disease of bone, high thyroid and parathyroid hormone levels can cause a high alkaline phosphatase, too.

Additional liver tests checking the GGT level or specifically what kind of alkaline phosphatase you have, by isoenzyme analysis can make the source of the elevated alkaline phosphatase clearer.

Getting an ultrasound scan and additional blood tests is a reasonable place to start. Unfortunately, lack of confidence in your physician is a different problem.

If you really cant get a new doctor, then you need to have a conversation about proceeding with evaluation in such a way that you can do so while being confident that you are getting good advice.

A few years ago, I read that the herbal supplement feverfew may help with some migraines. Having suffered with severe migraine for over 50 years, I decided to try it. I take one capsule four times a day, and it has completely rid me of my migraines. Would you please mention it again?

Feverfew is a common herbal remedy to prevent migraine, and although not all trials have shown benefit, the majority of studies I have read showed that it is more effective than a placebo and the side effect risk is very small.

Other nonprescription treatments that have been shown in most studies to be beneficial include magnesium, riboflavin and coenzyme Q10. They are generally safe and well-tolerated, and I hope others may get the same relief you have found.

View original post here:
To Your Good Health: What is treatment for a fatty liver? - Agri News

Recommendation and review posted by Bethany Smith

Delayed mammograms and breast cancer diagnoses during the COVID-19 pandemic may have a small long-term impact on breast cancer mortality rates up to 2030, according to results of a study with simulation modeling.

Findings from this study published in the Journal of the National Cancer Institute highlight the importance of continuing breast cancer screenings and evaluations in symptomatic women.

Some women simply skipped their mammogram if they were scheduled to undergo a mammogram during the pandemic, said Oguzhan Alagoz, who holds a PhD in industrial engineering and is a professor of industrial and systems engineering at University of Wisconsin-Madison, in an interview with CURE. What we are suggesting is rather than skipping the mammogram and waiting for your next mammogram whether it is in two years or next year this suggests you need to make up that missed mammography exam as soon as possible. Thats the primary means of undoing the impact of the pandemic.

When the COVID-19 pandemic first started, screening mammography and diagnostic mammography declined up to 80%, according to the studys introduction. There were also changes in breast cancer treatment protocols, which led to treatment delays and lower rates of chemotherapy administration.

In this short term, there was a huge reduction in the number of screenings (and) diagnoses, Alagoz said. The concern is if we have these short-term declines in breast cancer control activities, what will be the impact in the long term? Breast cancer is an interesting disease, where if you delay mammography, youre not going to see the full effect of it in six months or 12 months. Sometimes, some of these effects are seen in five years, 10 years.

To assess the potential long-term impact of breast cancer control disruptions during the COVID-19 pandemic, researchers used three established breast cancer models to simulate reductions in mammogram screenings, delays in the diagnosis of cancer in symptomatic patients and reductions in chemotherapy treatments for women with early-stage breast cancer. These scenarios were assessed within the first six months of the pandemic, when reduced screening rates were observed, following a return to patterns similar to before the pandemic.

Alagoz provided the reason as to why researchers only focused on the first six months of the pandemic rather than the entire pandemic.

By the end of the summer of 2020, many practices, clinics and health systems actually made up all of the missed mammography exams, Alagoz said. We have seen the screening volumes basically reach almost 100% capacity back in the summer. I (spoke) with our radiologist collaborators, (who) are telling me that they scheduled additional weekend and weeknight mammographic screenings.

Based on the model projections, researchers found that by 2030, there could be 950 cumulative excess breast cancer deaths related to reduced screenings during the COVID-19 pandemic. In addition, there could be 1,314 deaths from the delayed diagnosis of symptomatic patients and 151 deaths linked with reduced chemotherapy in women with hormone-positive, early-stage cancer. Collectively, there may be an estimated 2,487 excess breast cancer deaths, which represents a 0.52% increase in deaths by 2030 compared with models indicating breast cancer deaths without the effect of the COVID-19 pandemic.

Although any increase in mortality rates isnt ideal, Alagoz mentioned that these results were a pleasant surprise for his research team.

Before I started this study, I was really expecting a significant number of breast cancer mortality over the next 10 years due to the pandemic, Alagoz said. Fortunately, the impact is actually relatively small (in magnitude). I was expecting maybe 10,000 additional deaths, 15,000 additional (deaths), but our modeling suggests that we are going to see an additional 2,500 deaths over the next 10 years due to the pandemic.

He mentioned that these lower-than-expected increases in mortality rates are a somewhat positive finding of the study.

I think the silver lining in this unfortunate paper is that the impact is not as high as I was scared it would be, which is good news, Alagoz said. Primarily, that is because many practices after the initial shock of the pandemic and many patients were able to actually make up the exams and did resume the normal operations within a six-month period.

Alagoz added that delays during the COVID-19 pandemic did not greatly affect women who were already diagnosed with breast cancer.

Our findings show that disruptions didnt affect (these women) too much, Alagoz said. In other words, anybody who was supposed to get surgery, radiotherapy or chemotherapy, they already got the treatment. Oncologists aware of the really terrible potential effect of delaying the treatment or stopping the treatment didnt really change treatment practices very much. The patients who were already diagnosed with breast cancer prior to the pandemic, the effect of the pandemic on their care or mortality, we found, is limited.

Although there are some effects of the COVID-19 pandemic that can be undone, such as making up missed mammograms sooner rather than later, Alagoz said there are some consequences that cannot.

For example, many women during their self-exam (or) during their annual physician visit, they observe a palpable lump in their breast and then they go and visit the clinic, Alagoz said. And those cases dropped significantly during the pandemic. There is very little we can do to undo those effects. Those women already came for a delayed diagnosis, maybe like three months (or) six months later, and, unfortunately, there is not much we can do to undo that. But at least for the screening mammography exams that women (missed), we can certainly mitigate the impacts of the pandemic.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Continue reading here:
Disruption in Breast Cancer Care During COVID-19 Pandemic May Slightly Increase Long-Term Mortality - Curetoday.com

Recommendation and review posted by Bethany Smith

Insulin resistance, also known as impaired insulin sensitivity, is when someone has built a tolerance to insulin, the hormone responsible for regulating blood sugar levels.

Although insulin resistance precludes the development of type 2 diabetes, not everyone who has the condition will develop type 2 diabetes or its precursor, prediabetes. In fact, insulin resistance can be reversed with proper diet and exercise.

Here is what causes insulin resistance, how to recognize it, and the best treatment options.

Insulin resistance occurs when the cells in your muscles, fat, and liver are less responsive to insulin and therefore struggle to absorb glucose aka sugar in the blood.

Typically, you get a boost of sugar in your blood after you eat something containing carbohydrates. This boost signals to your pancreas to release insulin, which then helps your cells absorb the sugar and convert it to energy so you can function normally. Insulin resistance disrupts that process.

"When cells in the body become insulin resistant, more insulin is required to do the same job [aka lower blood sugar levels]," says Daniel Vatner, MD, an endocrinologist at Yale School of Medicine. "A person with insulin resistance needs to make much more insulin after a meal, or they will not be able to store and use sugar properly."

However, your body can only produce so much insulin on its own. So, there's a critical tipping point where your cells become so insulin resistant that they lose control over your blood sugar, and you end up with dangerous, chronically high blood sugar levels.

When there's too much sugar in your blood for too long, your body eventually stores it as fat. That's why insulin resistance increases the risk of being overweight and obesity-related conditions like:

Insulin resistance rarely comes with any noticeable symptoms. And most tests designed to detect insulin resistance are complicated and expensive.

Therefore, a healthcare provider will usually rely on tests that assess your blood sugar levels. These tests include:

All of these tests can also be used to diagnose prediabetes.

In rare cases, some people with insulin resistance may also develop a skin condition called acanthosis nigricans. This condition causes the skin to develop thick, dark, purplish patches, typically in the underarms, groin, or on the back of the neck.

Being overweight or obese can significantly increase your risk of insulin resistance, says Vatner.

"As an individual gains weight, fat can accumulate where it doesn't belong, as in the liver or the muscle," he says.

As fat gets into the cells, it can interfere with the cells' ability to respond to insulin, forcing the pancreas to make more insulin to compensate.

However, people of any size can also become insulin resistant.

You should regularly monitor blood sugar if you have risk factors for insulin resistance, such as obesity, a sedentary lifestyle, or a family history of type 2 diabetes . Even if you don't have these risk factors, you should start getting tested at the age of 45, says Mark Schutta, MD, medical director of the Penn Rodebaugh Diabetes Center.

Exercising and eating healthy are the most effective strategies for reversing insulin resistance. Even just a 5% to 10% loss in body weight can help to reverse insulin resistance, says Vatner.

Exercise not only plays an important role in weight management but can also help people with insulin resistance manage blood sugar. A 2016 review found that regular, moderately-intense physical activity like walking or biking for at least 30 minutes, three to five days a week was associated with improved insulin sensitivity as well as blood sugar control.

Schutta advises starting with a brisk 30- to 45-minute walk several days a week and then working your way up to 150 minutes of weekly moderate to vigorous aerobic exercise.

Important: Always consult with your physician before starting a new exercise program especially if you've been sedentary and/or have any pre-existing conditions to avoid injury.

Diet also plays a crucial role in managing and reversing insulin resistance. If you have insulin resistance, physicians may suggest you follow the Mediterranean diet, a plant-based diet, or a low-carb diet, like the Atkins diet.

In general, Schutta recommends limiting your intake of:

Schutta also recommends eating more:

Vatner says insulin-resistant patients with co-occurring conditions may be prescribed the following medications:

Insulin resistance is a serious, but treatable condition. If left untreated it could develop into prediabetes, metabolic syndrome, or type 2 diabetes, all of which increase your risk of heart disease and stroke.

While insulin resistance does not have any symptoms, it can be diagnosed through a blood sugar test.

To treat and reverse insulin resistance, eat a healthy diet full of fruits, vegetables, lean proteins, and whole grains while exercising for at least 150 minutes a week.

The rest is here:
How to reverse insulin resistance through diet and exercise - Insider

Recommendation and review posted by Bethany Smith

With the normal pressures of work compounded by the pandemic, stress and burnout are proliferating in the business world. Even before Covid-19, stress and burnout were ravaging the health of Americans. The number of hours worked is said by the non-profit American Institute of Stress to be the main source of job stress and this makes work especially problematic in the United States where Americans have a work ethic that is second to none.

A report a few years ago by the International Labor Organization showed that US workers averaged nearly 2,000 hours of work every year (40 hours per week x 52 weeks = 2,080 hours), or nearly 350 more hours per year (nine more weeks) than Europeans.

This is important because reducing stress is still the most important thing we can do for our health. Among other things, stress increases the risk of heart disease by 40 percent and the risk of stroke by 50 percent, and the American Institute of Stress tells us that three out of four doctors visits are for stress related ailments, and that stress is the basic cause of 60 percent of all disease and illness.

Whats the solution?

Many advocate shortening the work week. In Iceland, a trial from 2015 to 2019 of almost 3,000 people found that shortening the work week from 40 hours to 35 or 36 hours with no reduction in pay resulted in productivity either remaining the same or increasing over the working period, while perceived stress and burnout went down.

Microsoft Japan tried a four-day work week without a pay reduction over five weeks and reported happier workers and a 40% increase in productivity. And in 2018 Perpetual Guardian in New Zealand tried a four-day work week over 8 weeks for 240 of its staff. Employees there reported enjoying a better work-life balance and reported their stress levels decreased by 7%. The studies show that the workers reported less stress, but, of course, workers are motivated to praise shorter work weeks without pay reductions, and they may even be inspired to greater productivity during their working hours.

But there are doubters about this as a permanent solution, and, of course, some people find happiness in their work and dont want or need a shorter week. In all events, shortening the work week isnt a complete solution to stress and stress-induced disorders because of the myriad potential sources of stress that we encounter at work, at home, and in all our interactions. Is there then something we can add to better equip people to deal with the stresses and strains of life?

First, we should define stress to understand how we can best overcome it. Conversationally, we speak of the stress of the job or the stress of a divorce, ascribing the stress that people experience to an external event. However, more scientifically, stress refers to the internal bodily reactions to those events that are so disruptive to health.

The external events that are potentially stress-producing in the body are known as stressors or just stressful situations, to which individuals react very differently. One person in a given situation may suffer a stressful reaction such as a fight-or-flight response or a hormonal imbalance that can precipitate disease, whereas at least some people handle the situation with ease. Unfortunately, the latter appear to be in the minority.

A recent article in the Washington Post (What burnout really means, and what bosses and employees can do about it) tells us that the pandemic has caused prolonged stress to many, leading to burnout. Technically burnout is a combination of emotional exhaustion, and a reduced sense of personal accomplishment, and often a take this job and a shove it attitude. The author of the Post article says that experts say companies need to allow staff to set their own schedules, have meeting free days, proactively address rude workplace behavior, and avoid praising or normalizing working around the clock.

But these strategies, and even a shorter work week, seek to eliminate the stressors, but dont directly address the internal disorder that is stress, and they dont enhance our resilience to stressful stimuli. While eliminating stressors (if we can) may help in reducing future disruptions of the employees physical state, it does nothing to address the current internal disorder that leads to the headaches, stomach problems, high blood pressure, insomnia, and other stress-related disorders. And, of course, changing the work environment wont succeed for those companies unwilling or unable to change their environment. So, how do we overcome workplace stress?

Much stress is eliminated through night-time sleep. Although our bodies incur a heavy stress load on a regular basis, stress is a physical abnormality, which the body normalizes or heals whenever it is given the opportunity. When we become ill, we may relieve the symptoms with medicines, but Sir Hans Krebs, a Nobel Laureate in physiology, says The physician and the patient can do no more than assist nature, by providing the very best conditions for your body to defend and heal itself.

The rest we gain during sleep is a crucial requirement for assisting nature and allowing the body to heal itself. In fact, sleep is so important, it is part of every physicians prescription for virtually every disorder. However, while we naturally eliminate a lot of stress through sleep, the statistics tell us that most people are not winning their fight against stress and have come to accept being stressed as normal. We manage our stress with an increasing number of pharmaceuticals as we get older and think nothing of a full medicine cabinet to deal with our many disorders. If assisting nature is the key, what more can we do to help our bodies eliminate stress? How do we supplement our sleep if rest is so beneficial to health? This is where the yogis approach comes into play.

Research by co-author Dr. Wallace first published in Science and Scientific American in the 1970s showed that the meditation technique he analyzed, the Transcendental Meditation (TM) technique, produced a unique state of rest and orderliness in the mind and body, correcting physical disorders beyond what sleep had accomplished. His research showed that during the TM meditation session, the body gained a profound and unique state of rest. During the TM practice, even though the meditator was alert, the research showed remarkable decreases in oxygen consumption and respiration, reduced concentrations of blood lactate levels (high blood lactate is associated with anxiety), and a marked increase in skin resistance (associated with relaxation).

Later studies by Wallace and his colleagues showed reductions in cortisol (the stress hormone), as well as increases in serotonin (the happiness hormone), increases in blood flow to the brain, and perhaps most importantly, a marked coherence in the functioning of the brain. Sleep heals by creating order where there is disorder, but, interestingly, the rest during the Transcendental Meditation practice has been found to create more coherence, so in some respects it is more profound than what occurs during sleep.

The charts above show EEG brain wave measurements during sleep and the Transcendental Meditation technique. The mountains or spindles show periods when there is especially high coherence in the brain wave activity. High brain wave coherence is associated with memory, concept learning, creativity, high self-esteem, and reduced anxiety, depression, and other disorders, whereas abnormally low brain wave coherence is associated with autism, schizophrenia, Alzheimers, and other mental disorders. This is why researchers are so interested in studying brain waves.

And as can be seen from the charts, the individual who has been practicing TM for four months has significantly more brain wave coherence during the TM session than during sleep. And the five-year meditator has extremely high levels of brain wave coherence both during the meditation session and before and after meditating when just sitting with the eyes closed (see the EC or eyes closed period in the meditators charts). This is a level of coherence not found in other meditation practices.

Being resilient in the face of stress is also important since we cant possibly eliminate all the stressors in our lives. An article by Dr. Wallace recently published in Medicina describes a series of studies on TM that investigated the meditators response pattern to stressful stimuli as compared to a relaxation control group.

The meditators heart rates and other physiological measurements increased appropriately in response to stressful stimuli, but the meditators recovered much more quickly than the non-meditators, basically brushing off a situation that would tend to have a lasting effect on the non-meditators and disrupt their nervous systems. Dr. Wallace coined the phrase neuroadaptability to refer to the more resilient physiology that can better withstand stressful events.

Another interesting analysis by Dr. David Orme-Johnson, a former professor at Maharishi International University in Iowa (where all the students learn TM), determined that the number of medical visits of about 2,000 TM meditators were just a fraction of the number of visits of non-meditators of comparable age, gender, and profession, who had similar health insurance policies. Over the five-year study period, the TM meditators had significantly fewer incidents of illness in 17 medical treatment categories, including 87 percent less hospitalization for heart disease, 87 percent less for nervous system disorders, 73 percent less for nose, throat and lung diseases (including virus caused diseases), 65 percent less for metabolic disease, including diabetes, and 55 percent less for cancer.

Our new book, The Coherence Effect (Armin Lear Press, 2020), has many personal accounts of business people overcoming stressful work situations. Josh Griffith is one good example. He went from being burned out on the job to having the enthusiasm of a new hire. Josh has been the head writer for the popular daytime TV shows Days of Our Lives and The Young and the Restless. In 2013, he was having serious stress issues at work, and he started looking into meditation practices. Co-author Marcus interviewed Josh a few years ago after he had tried other techniques and had been practicing TM for a year. Josh said:

I saw a celebrated doctor on television and decided to try a meditation he said would help. So, I tried his meditation for about a year . . . . It was kind of helping, but then the work issues got worse and I was still feeling the same way that I had before.

Then Josh saw an interview about TM on television, and he decided to try it. He said:

In the world of daytime TV, youre having to create five shows a week. As head writer [The Young and the Restless] I was responsible for all the stories that aired. I walked away from it a few years ago because I felt burned out. It was too much of an output, and I didnt feel the quality of the output was something I could be proud of. It was taking such a toll on me that I walked away.

Then I started doing TM. I thought I was a meditator before starting TM. Boy, was I wrong. I was offered the head job on Days of Our Lives, and I agreed to take it because with TM I already felt sort of a creative energy bubbling back inside of me. So, I stepped back in, and it was sort of the case where I felt like Im back at the beginning of the career.

I felt like I had the energy that I had when I first started doing daytime. I was able to come in and the ideas flowed nonstop, whereas before I didnt know if I would be able to finish this. I was thinking I dont know what Im going to do Ive hit a wall. TM allowed me to generate so many story ideas that it was, in a way, sort of like a rebirth. You know Ive had a 30-year career. And the changes happened within a month of practicing TM. I feel like Im starting [my career] now. I feel like a 25-year-old again.

In years past, businesses have been slow to adopt meditation as a tool. That is changing and will change even more once businesses use brain-wave coherence as a means of evaluating different meditation programs. We have referred to some of the findings on Transcendental Meditation, a technique that we have each practiced for about 50 years. If you are interested in trying a meditation program, there are many to choose from, but we suggest letting science be the guide in selecting one, and we say the principal criterion needs to be the degree to which the program creates coherence in the mind and body, especially in the brain. Because the brain is the control center of the body, when the EEG activity is coherent, it has a maximum effect in creating the orderly and neurologically adaptive state that counteracts stress and makes us more resilient.

Written by Jay B. Marcus.

Read more from the original source:
A Yogi's Take on Stress and Burnout - CEOWORLD magazine

Recommendation and review posted by Bethany Smith

Females in Action South Coast is a Fall River-based organization for women that formed11 months ago during the COVID-19 pandemic.

Its member work out together at North Park in Fall River twice a week, Wednesdays at 6:15 p.m. and Saturdays at 8 a.m. There is no registration fee; just show up and get involved.

In addition to the workouts, members are also building friendships and helping their community along the way.

Organizer Caitlin Botelho and member Andrea Silvasaid this week on Townsquare Sunday that Females in Action is all about fitness, friendships, and philanthropy. The group has been involved in various charitable efforts during its first year.

Now the organization is looking to increase its numbers and expand to New Bedford.

Females in Action is actually a national programwith active groups in 20 states. It first began in North Carolina in 2013.

Caitlin Botelho, a Fall River native, was living in Tennessee at the time and became involved. She returned home in 2019 and started what's believed to be the first FiA chapter in the Northeast.

Both Caitlin and Andrea spoke about their experiences with FiA, and their hopes of getting more women involved. Their interview can be heard here:

Townsquare Sunday is a weekly public affairs program which airs Sunday at 6 a.m. and 11 am. on 1420 WBSM. The program highlights individuals and organizations working to make the SouthCoast a better place to live and work.

If you would like your organization featured on Townsquare Sunday, please e-mail the host at jim.phillips@townsquaremedia.com.

Read the original:
Fall River's Females in Action Hopes to Expand [TOWNSQUARE SUNDAY] - wbsm.com

Recommendation and review posted by Bethany Smith

TestoPrime is a dietary supplement that can help struggling with low testosterone levels. Testosterone is very important for overall male health as it can contribute to ones energy levels, stress response, muscle growth, sexual health and much more. It is common for men above the age of 40 to experience some sort of decline in their natural testosterone level. Issues such as erectile dysfunction, a lack of libido, weight gain, and low energy become common over time and even some younger people can suffer from the same problems. Taking a natural supplement that can boost the bodys natural testosterone levels can have a significant impact on ones overall health. TestoPrime is another addition to a long list of supplements that claim to boost natural testosterone levels in the body. Is the supplement worth purchasing? Does it work? Here is everything you need to know about TestoPrime.

Click Here to Visit the Official Website of TestoPrime

Who Is TestoPrime for?

TestoPrime is a natural supplement that anyone over the age of 18 can use. The supplement is intended for those men that are suffering from low testosterone levels as it can help bring them back to the level they need to be.

If youre experiencing some form of erectile dysfunction, low sex drive, low energy levels, fat gain, symptoms of depression, loss of body hair, chronic fatigue, and are extremely unmotivated, then you may be suffering from low testosterone levels. Testosterone is a very important hormone for male health, and it should not be overlooked.

(HUGE SAVINGS DEAL) Click Here To Buy TestoPrime at an Exclusive Low Price Today

TestoPrime is a natural supplement that can help improve the bodys ability to produce testosterone for great health benefits. The supplement is different from your average testosterone-booster as it consists of a natural formula that contains only pure and natural ingredients. TestoPrime also addresses the different reasons why your body may be suffering from low T-levels and promotes overall well-being without side-effects.

While many male enhancement supplements tend to have nasty side-effects, that is not the case with TestoPrime. The supplement consists of different antioxidants, minerals, and other nutrients that help improve the different mechanisms within the body for optimal health. Since the composition of the formula relies on natural ingredients, there are no side-effects making the supplement safe to consume. Although a prescription is not required to use TestoPrime, you should still consult your doctor if you are suffering from any other underlying health problem.

Overall, TestoPrime looks like the answer to the common problems faced by most men. If you are facing any of the problems mentioned above, then consider TestoPrime as its a safe and affordable option.

MUST SEE:We Found an Amazing Discounted Price For TestoPrime Pills Right Here

How Does It Work?

TestoPrime works by using a natural formula full of different powerful ingredients that support the bodys natural testosterone production mechanisms. However, thats not the only thing the supplement does, otherwise it would just be another testosterone booster. The ingredients inside the supplement also target the different things inside the body that could be contributing to low testosterone levels.

For example, stress is a big contributor to low T-levels and the supplement works inhibit the stress hormone cortisol to reduce the impact it has on the bodys testosterone levels. Similarly, there are different mechanisms inside the body that are responsible for converting testosterone into DHT (an androgen derived from testosterone), and estrogen. The ingredients inside the supplement work to reduce such mechanisms and prevent the conversion of testosterone. By reducing the rate at which testosterone is converted, and by promoting natural production of testosterone, TestoPrime can help support healthy T-levels in the body for fantastic health benefits.

Click Here to Get Testo Prime For The Lowest Discounted Price Online

Moreover, everything about TestoPrime is 100% safe and natural. As youll see listed below, the supplement uses a completely natural formula full of different ingredients that you may have already heard of. The manufacturers simply bring all the best ingredients under one supplement and use their purest and most potent forms for the best results. There are no side-effects of taking TestoPrime, and the manufacturing process also follows all the good manufacturing practices which helps keep the quality high.

Therefore, if youre in the market for a supplement that can help improve your health naturally, then TestoPrime might be the right choice for you. However, its recommended that one does their own research as well in order to make an informed decision.

ACT NOW AND SAVE! Get Testo Prime At an Amazing Discounted Price Online

TestoPrime Ingredients

>> Visit the Testo Prime official website today to place your order

(LIMITED SUPPLIES) Click Here to Buy TestoPrime at The Best Available Price Online

Benefits of TestoPrime

Some of the worth noting health benefits of TestoPrime are:

>> Also check what others are saying about this testosterone supplement. Does It Really Work? Click Here To Check Out TestoPrime Customer Reviews Now.

>> Try TestoPrime Now Visit the official website today to place your order.

Bonus Items

TestoPrime comes with two additional e-books free of cost if you opt for more than one bottle at checkout. These e-books are great resources for getting the most out of the supplement. The e-books are:

Pricing and Refund Policy

TestoPrime is a reasonably priced supplement that comes in three differently priced bundles priced as follows:

The price per bottle decreases as you go for the multi-bottle deals, and they become even better value for money thanks to the two free e-books that come with them. Each purchase of TestoPrime is also protected by the manufacturers 100% satisfaction guarantee. You can use the supplement for yourself and if you feel like it is not working out for you, then you can opt for a full refund; no questions asked.

Does TestoPrime Really Work?

TestoPrime has potential to be one of the best supplements out there. Men all over the world face many problems with their health due to low T-levels and the supplement can help counter that with its natural formula. TestoPrime can help improve muscle growth, reduce stress, promote fat loss, and much more thanks to a safe, and natural formula. The supplement also comes with two free guides that can help amplify its benefits. No side-effects, and the fact that the manufacturer is offering a money-back guarantee speaks volumes about the confidence they have in their product. Therefore, TestoPrime seems like a risk-free investment and worth a buy if youre looking to naturally boost your testosterone levels. You can purchase it from here.

SAFE PURCHASE Try TestoPrime on a Special Discounted Price Right Now

Disclaimer

Please note that any guidelines and advice given here are not a substitute for medical advice. Please consult your physician if you are under medication or have doubts following the advice/instructions given. Individual results may vary.

View post:
TestoPrime Reviews - Testo Prime Testosterone Booster - The Ritz Herald

Recommendation and review posted by Bethany Smith

DUBLIN, July 15, 2021 /PRNewswire/ -- The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global stem cell banking market exhibited strong growth during 2015-2020. Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy. It is the process of extracting, freezing and storing stem cells for potential future use. Some of the sources through which stem cells are obtained include embryo, umbilical cord, cord blood, placenta and bone marrow. These cells are used for treating a number of different diseases including diabetes, thalassemia, leukemia, sickle cell anemia and cardiac diseases. Moreover, they are also employed for generating platelets, red blood cells and white blood cells. The potential of stem cells to regenerate has led to their applications in tissue engineering, gene therapy and regenerative medicines. Looking forward, the publisher expects the global stem cell banking market to reach a value of US$ 21.5 Billion by 2026.

Global Stem Cell Banking Market Drivers:

Competitive Landscape:

The market is fragmented in nature with the presence various international as well as regional players.

Some of the leading players operating in the market are:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Properties

4.3 Key Industry Trends

5 Global Stem Cell Banking Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Breakup by Product Type

5.5 Market Breakup by Service Type

5.6 Market Breakup by Bank Type

5.7 Market Breakup by Utilization

5.8 Market Breakup by Application

5.9 Market Breakup by Region

5.10 Market Forecast

6 Market Breakup by Product Type

6.1 Adult Stem Cells

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Human Embryonic Cells

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 IPS Cells

6.3.1 Market Trends

6.3.2 Market Forecast

7 Market Breakup by Service Type

7.1 Sample Preservation and Storage

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Sample Analysis

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Sample Processing

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Sample Collection and Transportation

7.4.1 Market Trends

7.4.2 Market Forecast

8 Market Breakup by Bank Type

8.1 Private

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Public

8.2.1 Market Trends

8.2.2 Market Forecast

9 Market Breakup by Utilization

9.1 Used

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Unused

9.2.1 Market Trends

9.2.2 Market Forecast

10 Market Breakup by Application

10.1 Personalized Banking Applications

10.1.1 Market Trends

10.1.2 Market Forecast

10.2 Research Applications

10.2.1 Market Trends

10.2.2 Market Forecast

10.3 Clinical Applications

10.3.1 Market Trends

10.3.2 Market Forecast

11 Market Breakup by Region

11.1 North America

11.1.1 Market Trends

11.1.2 Market Forecast

11.2 Europe

11.2.1 Market Trends

11.2.2 Market Forecast

11.3 Asia Pacific

11.3.1 Market Trends

11.3.2 Market Forecast

11.4 Middle East and Africa

11.4.1 Market Trends

11.4.2 Market Forecast

11.5 Latin America

11.5.1 Market Trends

11.5.2 Market Forecast

12 Global Stem Cell Banking Industry: SWOT Analysis

12.1 Overview

12.2 Strengths

12.3 Weaknesses

12.4 Opportunities

12.5 Threats

13 Global Stem Cell Banking Industry: Value Chain Analysis

14 Global Stem Cell Banking Industry: Porters Five Forces Analysis

14.1 Overview

14.2 Bargaining Power of Buyers

14.3 Bargaining Power of Suppliers

14.4 Degree of Competition

Read more here:
Insights on the Stem Cell Banking Global Market to 2026 - by Product Type, Service Type, Bank Type, Utilization, Application and Region - WFMZ...

Recommendation and review posted by Bethany Smith

Scientists say that base editing proved itself efficient in correcting a mutation in patient cells with the monogenic disease Alpha-1 antitrypsin deficiency (AATD). The disorder is a common inherited disease that affects the liver and the lungs.

Base editing is different from other forms of editing, including CRISPR, because the base editors do not induce a break in the DNA, which helps prevent double strand breaks, potential off-target editing, and unwanted mutations during cell repair.

Researchers at Boston Medical Center and Boston University used patient-derived liver cells (iHeps) that mimic the biology of liver hepatocytes, the main producers of alpha-1 antitrypsin protein in the body. The base editing technology corrected the Z mutation responsible for AATD and reduced the effects of the disease in the hepatocytes, demonstrating successful base editing in human cells.

The study (Adenine Base Editing Reduces Misfolded Protein Accumulation and Toxicity in Alpha-1 Antitrypsin Deficient Patient iPSC-Hepatocytes), published inMolecular Therapy,can help pave the way for future human trials, according to the research team.

AATD is most commonly caused by the Z mutation, a single base substitution that leads to AAT protein misfolding and associated liver and lung disease. In this study, we apply adenine base editors to correct the Z mutation in patient-induced pluripotent stem cells (iPSCs) and iPSC-derived hepatocytes (iHeps), wrote the investigators.

We demonstrate that correction of the Z mutation in patient iPSCs reduces aberrant AAT accumulation and increases its secretion. Adenine base editing (ABE) of differentiated iHeps decreases ER stress in edited cells as demonstrated by single-cell RNA sequencing. We find ABE to be highly efficient in iPSCs and do not identify off-target genomic mutations by whole genome sequencing.

These results reveal the feasibility and utility of base-editing to correct the Z mutation in AATD patient cells.

This study shows the successful application of base editing technology to correct the mutation responsible for AATD in liver cells derived from patients with this disease, said Andrew Wilson, MD, a pulmonologist at Boston Medical Center and an associate professor of medicine at the Boston University School of Medicine, who served as the studys corresponding author. I am hopeful that these results will create a pathway to use this technology to help patients with AATD and other monogenic diseases.

Base editors created by Beam Therapeutics were applied to induced pluripotent stem cells (iPS cells) from patients with AATD, and then again in hepatocytes that were derived from iPS cells. This was done to study the correction of the Z mutation of the gene responsible for AATD in human cells.

The Z mutation in the SERPINA1 gene is responsible for causing chronic, progressive lung and liver disease in AATD. In patients with AATD, the mutant AAT proteins misfold and form aggregates of protein that build up inside the hepatocytes and cause damage.

For this study, researchers started with mutant (ZZ) iPSCs created from a patient with AATD. After the base editing process was completed, the DNA from the edited cells was sequenced to determine if the SERPINA1 gene had been corrected. Clonal populations of cells with either one (MZ) or both copies (MM) of the corrected gene were expanded and then differentiated over the course of 25 days to generate hepatocytes.

After sequencing the entire genome of the edited cells, there was no evidence of inadvertent mutations in the genome from the base editors, and the misfolding and associated protein buildup was partially corrected in MZ cells and completely in MM normal cells.

The process was repeated using hepatocytes derived from the mutant iPSCs. Two base editors were used in different conditions to test the efficiency of this process. In the best conditions, about 50% of the mutant genes were successfully edited. The cells were then analyzed to see if they still appeared hepatic and if there were fewer signs of the disease in the edited cells, compared to mutant ZZ cells.

Findings showed the base editing did not alter the hepatic program, and the liver cells still expressed hepatic genes and proteins at normal levels. In addition, there was less accumulation of aggregated misfolded Z AAT protein, showing less evidence of disease in the edited cells.

While augmentation therapy has been shown to slow the progression of lung disease in AATD patients, there are currently no treatments available for AATD-associated liver disease. Emerging treatment strategies have focused on the correction of the Z mutation.

Base editing is being evaluated as a treatment modality for a variety of monogenic diseases, according to the scientists. Alpha-1 antitrypsin deficiency is a prime target for base editing, likely to be one of the earlier diseases in which base editors are tried in human studies. Additional disease targets include retinal disease, hereditary tyrosinemia, sickle cell anemia, progeria, cystic fibrosis, and others.

Findings of this study suggest that future research may explore the usefulness of base-editors in editing other quiescent cell populations. Additionally, it has recently been shown that base-editors can edit RNA in addition to DNA in immortalized cell lines and warrants further investigation.

By quiescent, we are referring to differentiated cells (in this case hepatocytes) that are not stem cells or cells that are actively dividing. Basically, [we are talking about] any differentiated cell type, Wilson toldGEN. This is relevant because many of the cell types in the body that you would want to target are already differentiated cells. It is in many cases easier to edit an actively dividing cell, which is why we mention this. There are many examples of a differentiated cell type in the body, such as cardiac cells, lung cells, skin cells, etc., that you might want to target.

One of the major things researchers worry about in the field of gene editing is the possibility of off-target effectsunintended consequences of applying the editing machinery.

The most likely off-target effect, in this case, would be editing of DNA somewhere in the genome other than what we intended to edit, continued Wilson. When we looked by whole genome sequencing, we didnt see evidence of this in iPS cells. However, in addition to editing DNA, it has been reported that base editors can also edit RNA. This could have unintended consequences even if the DNA sequence isnt changed.

We didnt look in this study to see if this occurred, which is why we mentioned itjust to be up front about possible unintended consequences/toxicities that could be present and that we didnt exclude. It isnt something specific to our study or gene of interest but generalizable to the entire field of base editing.

Read more:
Base Editing as Therapy for Common Inherited Lung and Liver Disease Shows Promise - Clinical OMICs News

Recommendation and review posted by Bethany Smith

SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemsons proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemsons efforts to restore human hair growth with a novel cell regeneration technology using the patients own cells to generate new hair follicles.

In addition, Kiersten Stead, Ph.D., Co-Managing Partner at DCVC Bio and Jenny Rooke, Ph.D., Managing Director at Genoa Ventures will join Stemsons Executive Chairman Matt Posard and Chief Executive Officer and co-founder Geoff Hamilton on the board of directors. Dr. Stead invests in early-stage companies that build novel deep tech businesses in the life sciences. Stead received a Ph.D. in Molecular Biology & Genetics and an MBA in finance from the University of Alberta. Dr. Rooke is founder and Managing Director at Genoa Ventures where she specializes in early-stage companies innovating at the convergence of technology and biology. Rooke received a Ph.D. in Genetics from Yale University and a degree in physics from the Georgia Institute of Technology.

We are excited and honored to welcome DCVC Bio and a fantastic syndicate of investors to the Stemson team. The Series A funding will help us optimize our solution for human skin structure and environment so we can go into our first human clinical trial with high confidence for a positive outcome. We have the technical and biological building blocks to successfully address hair loss that overcomes failures of past therapies, said Hamilton. The addition of key venture capital investors DCVC Bio, Genoa Ventures and AbbVie Ventures broadens and strengthens our investor base. DCVC Bio and Genoa Ventures are successful early-stage development investors, and I am pleased to welcome Dr. Stead and Dr. Rooke, our newest board members, to the team. In addition, the AbbVie Venture investment comes on the heels of an initial seed investment from Allergan Aesthetics in 2020, and the continued industry interest in our technology is encouraging.

Globally, hundreds of millions of men and women suffer from various forms of hair loss. Though there are many possible causes of hair loss, including chemotherapy, autoimmune disease, scarring, and genetics, all can result in a loss of self-esteem and cause depression, anxiety and other mental health disruption for those affected. The hair restoration market is expected to exceed $13.6 billion by 2028, and no solution today is capable of generating an unlimited new supply of healthy follicles for patients in need.

Almost 30 years have passed since the last FDA-approved hair loss treatment, yet millions still suffer the physical and mental impact of losing their hair each year, stated Dr. Stead. Stemsons novel stem cell engineering platform has the potential to cure hair loss once and for all, treating not only the physical symptoms of this complex problem, but the mental burden as well.

"The team at Genoa is impressed with Stemsons vision to blend biology and technology and apply it beyond traditional biotech," added Dr. Rooke. "By combining exciting advancements in iPSCs with novel technologies in materials and data sciences, Stemson exemplifies the kind of chimeric teams Genoa seeks to support on their journey to become a category-defining company."

The Series A financing brings the total funding raised to date to $22.5 million and allows Stemson to further the next stage of research and development of its cell engineering platform, where is it being combined with bioengineered material and robotic delivery as a novel solution for natural hair replacement. Currently, Stemsons research and development efforts are focused on developing an optimized solution for human skin structure environment in larger animal models. Stemsons Induced Pluripotent Stem Cell (iPSC) based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.

About Cell Regeneration Technology

Human Induced Pluripotent Stem Cells (iPSC) have the unique capability to replicate indefinitely and give rise to all cell types of the human body, including the cell types required for repair. iPSC-based technology is capable of producing the cell types required to initiate hair follicle growth. As a new therapeutic platform, iPSCs represent an emerging area of regenerative cell therapy. Stemson is one of a growing number of companies at the forefront in developing iPSC-based treatments.

About DCVC Bio

For over twenty years, DCVC and its principals have backed brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry. DCVC Bio specializes in supporting life sciences platform companies at the intersections of engineering and therapeutics, industrial biotechnology and agriculture. For more information, please visit https://www.dcvc.com/companies.html#dcvc-bio

About Genoa Ventures

Genoa Ventures invests in early-stage companies working at the convergence of biology & technology to accelerate the pace of innovation, transform industries, and solve some of the most fundamental challenges to life. Genoa, identifies opportunities early and focuses its investments and expertise to empower the next great category-defining companies. The Genoa team has a unique chimeric blend of experience from scientific research and discovery to executive management in the life sciences and technologies sectors. The team applies this diverse experience to provide expert guidance to its companies and stellar returns to its investors.

About AbbVie Ventures

AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization. For more information, please visit http://www.abbvie.com/ventures

About Stemson Therapeutics

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia. Today, there are no available treatments capable of growing new hair follicles. Stemsons world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.stemson.com.

Read the original:
Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss - Business Wire

Recommendation and review posted by Bethany Smith

Some people involved in a class action against two fertility services over the use of a non-invasive test which may have incorrectly classifiedembryos as abnormalhave been told their embryos are still being stored.

The lawyer representing about 200 affected parties in Victoria's Supreme Court saidthe mistake hadresulted in some women choosing to beimplanted with another person's embryo, while others have lost precious months of fertility.

The class action launched lastDecember alleges Melbourne-based Monash IVF and Adelaide-based Repromed breachedtheir duty of care by failing to tell patients about the pitfalls of a type of testing that does not require a biopsy.

There are two ways to conduct such testing: the first method is through a biopsy, which involves taking a tissue sample from an embryo, a method that is considered invasive.

The second method is called non-invasive pre-implantation genetic testing and involves collecting DNA from the culture that the embryo has been growing in while in the laboratory.

The inaccuracy of the test used by the two services between May 2019 and October 2020 was discovered last October.

Patients were informed of the issue after manyhad already made the choice to donatethe embryos to science or destroy them.

Lawyer Michel Margalit said some clients had discovered last week that some oftheir embryos were still in storage.

Supplied

Those that had been donated could still be retrieved, but the others were lost forever.

"They acted on the advice that their embryos were abnormal or had been destroyed," Ms Margalit said.

"Some people obtained donor embryos and are now pregnant with children that aren't necessarily genetically related to them, or that had a whole host of other treatments, so it's a very painful time for our clients."

She said they were not told about the pitfalls of the experimental testing regime.

"In this case, there was an alternative a reliable test, a biopsy method and women were steered away from that method, to this non-invasive method and they just didn't know the mess they were walking into," she said.

Monash IVF and Repromed have now stopped using non-invasive pre-implantation genetic testing.

Repromed medical directorProfessor Kelton Tremellen said the test turned out to be not as accurate as the company had hoped.

He said some of the embryos that could now be used might still be abnormal.

Supplied: Repromed

"What we're trying to do is say, look, unfortunately, we've now recognised that the test is not as accurate as it was originally portrayed to us and that we want to give these individuals the opportunity to make a decision nowwhat they want to do with those embryos," he told ABC Radio Adelaide.

"Some people will say 'I simply don't want to use them, we've moved on'.

"Others will say, 'look, we'll accept the risk and transfer them and effectively consider them to be embryos that haven't been tested at all'."

He said he and other scientists had "lost sleep" worrying about the effect on patients.

"Rather than hide this stuff from patients, our staff have contacted them saying, 'look, those embryos are still in storage, we've now found out this test is not as accurate as we'd hoped, what would you like to do with them?'" he said.

"Rather than sweeping it under the carpet, we're trying to be open and socially responsible by having full disclosure."

Continue reading here:
IVF patients suing over inaccurate genetic tests find out some of their embryos were not discarded - ABC News

Recommendation and review posted by Bethany Smith

Small-cell lung cancer (SCLC) occurs almost exclusively in smokers and appears to be most common in heavy smokers. Historically, SCLC has been rare in never smokers. However, certain inherited mutations may increase the likelihood of developing SCLC.

It is very important to note that having inherited a genetic mutation does not mean a person will develop SCLC.

Although there are several different kinds of lung cancer, around 95% of lung cancers are either SCLCs or non-small cell lung cancers (NSCLCs).

What distinguishes SCLC from NSCLC is its rapid growth and the early development of widespread metastases. Although SCLC is initially very responsive to chemotherapy and radiation, the majority of patients will relapse within a few months to 1 year from initial therapy.

This article will look at whether SCLC is hereditary and whether a person can undergo genetic testing. It will also discuss the causes of and risk factors for SCLC.

SCLC occurs when certain cells in the lungs grow quickly and uncontrollably, forming a tumor.

Cancers begin to develop when genetic mutations affect the genes that control the growth and division of cells or repair DNA that is damaged.

The majority of lung cancer cases are due to genetic changes known as somatic mutations, which are not hereditary. A person acquires them during their lifetime.

The National Organization for Rare Disorders notes that the two main somatic mutations related to SCLC affect the genes TP53 and RB1.

The TP53 gene provides instructions for creating a protein called p53, and the RB1 gene provides instructions for making pRB. Both proteins are tumor suppressors, which means they regulate cell growth and division.

However, in 2021, a group of researchers published a scientific paper that looked at 87 people with SCLC.

After analyzing 607 genes from each individual, the researchers found genetic mutations that increased the likelihood of developing SCLC in 43.7% of the study participants. Around 10% of these are heritable genetic mutations.

The authors of the paper conclude that certain heritable genetic mutations could make some people more likely to develop SCLC.

It is of note that if a person inherits a genetic mutation, this can increase their risk of developing cancer. It does not mean, however, that they will definitely develop cancer.

In addition, the American Cancer Society states that, although genes can play a role in the development of lung cancer, few lung cancers occur due to inherited mutations alone.

Genetic testing is when healthcare professionals look for potential inherited genetic mutations that may increase a persons risk of developing certain kinds of cancer.

For some cancer types, a healthcare professional can also suggest genetic testing as a part of the diagnostic and staging process. This can help determine a persons outlook and whether particular treatment options might be helpful.

Currently, however, doctors do not use genetic testing to diagnose SCLC. The Memorial Sloan Kettering Cancer Center notes that healthcare professionals and researchers know less about the genetic mutations that can lead to SCLC than they do about other genetic changes.

Smoking is the primary cause of SCLC. Tobacco smoke contains cancer-causing chemicals, or carcinogens, which damage the DNA in cells.

According to a 2020 review, 85% of lung cancer cases are the result of smoking.

Other risk factors include exposure to:

There are several ways in which a person may be able to lower their risk of developing SCLC.

Smoking tobacco is such a common cause of SCLC that the most effective preventive strategy is to not begin smoking.

However, for those who do smoke, quitting can lower the likelihood of developing SCLC. If a person quits before cancer develops, the lung tissue can begin to gradually repair itself.

A 2018 study looked at a group of people who have smoked 21.3 packs of cigarettes per year on average. The researchers compared the lung cancer rates of those who currently smoke and those who had quit within the previous 5 years.

They found that the individuals in the latter group were 39.1% less likely to develop lung cancer.

Learn about 11 tips for giving up smoking here.

Other ways of lowering the risk of SCLC include reducing exposure to secondhand smoke, asbestos, and radon. However, this may sometimes be outside of a persons control.

At the moment, doctors do not use genetic testing to diagnose SCLC.

Instead, a person should contact a healthcare professional if they experience any of the following symptoms:

If a healthcare professional suspects the cause of the above symptoms is SCLC, they may perform the following diagnostic tests:

Cancer occurs due to genetic mutations that lead to an uncontrollable growth and division of cells.

A person can acquire these genetic mutations throughout their life. In some cases, certain hereditary genes can increase the risk of developing SCLC.

However, inherited genetic mutations are often not enough to cause cancer by themselves. Having inherited a genetic mutation does not mean a person will develop cancer. It means that it can increase the likelihood of that happening.

Smoking is the primary cause of SCLC. To help lower the risk of developing this type of cancer, a person should avoid smoking.

Read the original:
Is small-cell lung cancer hereditary? What to know - Medical News Today

Recommendation and review posted by Bethany Smith

NEW YORK Foundation Medicine and Flatiron Health announced this week that Foundations comprehensive genomic profiling tests will be available to order through Flatiron's OncoEMR platform. The integration will allow clinicians to electronically order, track, and receive Foundations test through OncoEMR, the companies said. Both Flatiron and Foundation are planning further integrations with the others comprehensive genomic profiling tests and electronic medical record systems, respectively.

Myriad Genetics this week said it has completed the sale of its Myriad RBM unit which specializes in providing laboratory research services to pharmaceutical companies to IQVIA subsidiary Q2 Solutions. When Myriad announced its intent to sell this business unit in May, it did not disclose the deal's financial details.

GenetronHealth said this week that it has entered a new partnership with the World Economic Forum under its Health and Healthcare Platform, where it is contributing its research insights, technologies, and industry experience. The platform's overall goal is to ensure worldwide equal access to the highest standards of health and healthcare.Genetroniscurrentlyparticipating in a sub-project,dubbedMoving Genomics to the Clinic, which seeks to promote the use of genetic testing in routine clinical practices by proving its utility and efficacy.

AccessHope, a City of Hope subsidiary, said this week that it has partnered with the Dana-Farber Cancer Institute to bring the latest cancer care expertise to patients and oncologists in the community. By partnering withAccessHope, Dana-Farber's experts will support oncologistswiththe latest advances in oncology,includingpersonalized treatments, clinical trials, promising investigational medications, and molecular testing. Patients in Massachusetts, Maine, New Hampshire, Vermont, Connecticut, Rhode Island, New York,and New Jersey, as well asthosein other parts of the country,can access these services through their employee benefits programs. City of Hope and Northwestern University's Robert H. Lurie Comprehensive Cancer Center are also foundational members ofAccessHope.

Molecular breath analysis startup Deep Breath Intelligencesaid this week that it has entered a collaboration with Lwenstein Medical, a sleep and respiratory medicine firm based inRheinland-Pfalz, Germany.Rotkreuz, Switzerland-based DBI said that it is applying artificial intelligence to identify breath biomarkers related to obstructive sleep apnea syndrome. DBIsaid ithas initiated a study on OSASin collaboration with Lwenstein Medical,using participantsbreath samples and applying DBIs patterned analytical algorithms to provide results.

Enable Biosciences said this week it is partnering with the California Department of Public Health to survey state residents for the presence of antibodies against SARS-CoV-2. As part of the program, more than 200,000 households in California will be invited to submit dried blood samples collected at home using kits developed by Enable Bio andtheCDPH. The samples will then be tested by Enable Bio for the presence of antibodies against SARS-CoV-2 to distinguish antibody response fromviralinfection versusresponse fromvaccination. Test results will provide information about the spread of COVID-19 in California and the uptake of vaccines for the disease, South San Francisco, California-based Enable Bio said. The project is a collaboration betweenthe company,theCDPH, Stanford University, and Gauss Surgical. The first survey period concluded June 15 with the second and third enrollment periods slated tobeginat the start of 2022.

NeoGensaid this week that it has extended itsglobalanimal genomicspartnership withGencove. Thepartnership allowsNeoGento offerGencove'sSkimSeeklow-pass sequencing technology to customers in the agricultural sector, including those in the bovine, canine,poultry, and swine industries. UsingGencove'ssequencingimputationplatform,NeoGensaid it can deliver increased genomics data with improved accuracy and flexibility.

Bioceptsaid this week ithas been added to the Russell Microcap Index. Michael Nall, Biocept's president and CEO,called the nodexceptionally exciting, as a driver ofawarenessfor the cancer liquid biopsy firm within thelargerglobal investment community.

Immunoviasaid this week that its American subsidiary hasreceived a CLIA Certificate of Registration,which isan important step in the accreditation of its laboratory in Marlborough, Massachusetts, and a prerequisite to receiving clinical laboratory licensure fromtheMassachusetts Department of Public Health. Clinical laboratory licensure is required beforeImmunoviacan begin testing patients with itsImmrayPanCan-d test, the firm said.According to the Centers for Medicare and Medicaid Services, a Certificate of Registration allows a laboratory toconduct moderate and/or high complexity testing until it is inspected to determine its compliance with the CLIA regulations.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared onGenomeWeb.

Continued here:
In Brief This Week: Foundation Medicine, Myriad Genetics, Genetron Health, and More - GenomeWeb

Recommendation and review posted by Bethany Smith

Dublin, July 05, 2021 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening potential Market Size, Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. While Pharmaceutical Companies see the potential to make nearly any therapy viable. The report has data on how test volumes have grown for the biggest players. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Key Topics Covered:

1 Market Guides

2 Introduction and Market Definition

3 Market Overview3.1 Players in a Dynamic Market3.1.1 Academic Research Lab3.1.2 Diagnostic Test Developer3.1.3 Instrumentation Supplier3.1.4 Distributor and Reagent Supplier3.1.5 Independent Testing Lab3.1.6 Public National/regional lab3.1.7 Hospital lab3.1.8 Physician Office Labs3.1.9 Audit Body3.1.10 Certification Body3.2 Oncogenomics3.2.1 Carcinogenesis3.2.2 Chromosomes, Genes and Epigenetics3.2.2.1 Chromosomes3.2.2.2 Genes3.2.2.3 Epigenetics3.2.3 Cancer Genes3.2.4 Germline vs Somatic3.2.5 Gene Panels, Single Gene Assays and Multiplexing3.2.6 Genomic Profiling3.2.7 The Comprehensive Assay3.2.8 Changing Clinical Role3.2.9 The Cancer Screening Market Opportunity3.3 Cancer Management vs. Diagnosis3.3.1 The Role of Risk Assessment3.3.2 Diagnosis3.3.3 Managing3.3.4 Monitoring3.4 Phases of Adoption - Looking into The Future3.5 Structure of Industry Plays a Part3.5.1 Hospital Testing Share3.5.2 Economies of Scale3.5.2.1 Hospital vs. Central Lab3.5.3 Physician Office Lab's3.5.4 Physician's and POCT3.6 Currently Available Large Comprehensive Assays3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing3.7.1 Medicare Profile Pricing3.7.2 Whole Exome Sequencing

4 Market Trends4.1 Factors Driving Growth4.1.1 Level of Care4.1.2 Companion Dx4.1.3 Immuno-oncology4.1.4 Liability4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 State of knowledge4.2.2 Genetic Blizzard4.2.3 Protocol Resistance4.2.4 Regulation and coverage4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Single Cell Genomics Changes the Picture4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay

5 Cancer Panels & Profiles Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Dante Labs Acquires Cambridge Cancer Genomics5.3 Celemics, Strand Partner on Integrated Platform for NGS Analysis5.4 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries5.5 Burning Rock Revenues Rise5.6 Caris Life Sciences to Expand Liquid Biopsy Testing5.7 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence5.8 Intermountain and Myriad Combine Test Offering5.9 Illumina, Geneseeq to Offer Cancer Testing Kits in China5.10 Exact Sciences to Offer End-to-End Cancer Testing5.11 Guardant Health Turns to Tumor Tissue Sequencing5.12 Tempus Inks Oncology Testing Collaboration With Bayer5.13 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform5.14 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test5.15 Metastatic Cancer Markers Identified in Clinical WGS Study5.16 Stitch Bio Bets on CRISPR Tech5.17 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program5.18 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx5.19 Progress, Challenges in Liquid Biopsy Reimbursement5.20 Israeli Startup Curesponse Raises $6M5.21 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings5.22 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution5.23 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program5.24 Germline Results Guides Precision Therapy in Advanced Cancer5.25 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics5.26 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers5.27 Labs Reporting Cancer Risk Mutations from Tumor Testing5.28 Users Begin Integrating Genomics Data for Clinical Decision Support5.29 Fujitsu Improves Efficiency in Cancer Genomic Medicine5.30 Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results5.31 Universal Genetic Testing for All Breast Cancer Patients5.32 Exact Sciences buys Genomic Health5.33 Multi-Gene Liquid Biopsy Breast Cancer Panel5.34 Thrive to Develop Earlier Detection of Multiple Cancer Types5.35 New Gene Panel Identifies High Risk Prostate Cancer5.36 Guardant Health Liquid Biopsy Test to be Covered by EviCore5.37 Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services5.38 Natera Commercializes Tumor Whole Exome Sequencing from Plasma5.39 Inivata Completes 39.8M Series B Funding Round5.40 Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance5.41 CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials5.42 Biodesix Acquires Integrated Diagnostics5.43 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

6 Profiles of Key Players6.1 10x Genomics, Inc6.2 Abbott Diagnostics6.3 AccuraGen Inc6.4 Adaptive Biotechnologies6.5 Aethlon Medical6.6 Agena Bioscience, Inc6.7 Agilent/Dako6.8 Anchor Dx6.9 ANGLE plc6.10 ApoCell, Inc.6.11 ArcherDx, Inc6.12 ARUP Laboratories6.13 Asuragen6.14 AVIVA Biosciences6.15 Baylor Miraca Genetics Laboratories6.16 Beckman Coulter Diagnostics6.17 Becton, Dickinson and Company6.18 BGI Genomics Co. Ltd6.19 Bioarray Genetics6.20 Biocartis6.21 Biocept, Inc6.22 Biodesix Inc6.23 BioFluidica6.24 BioGenex6.25 BioIVT6.26 Biolidics Ltd6.27 bioMerieux Diagnostics6.28 Bioneer Corporation6.29 Bio-Rad Laboratories, Inc6.30 Bio-Reference Laboratories6.31 Bio-Techne6.32 Bioview6.33 Bolidics6.34 Boreal Genomics6.35 Bristol-Myers Squibb6.36 Burning Rock6.37 Cancer Genetics6.38 Caris Molecular Diagnostics6.39 Castle Biosciences, Inc.6.40 Celemics6.41 CellMax Life6.42 Cepheid (Danaher)6.43 Charles River Laboratories6.44 Chronix Biomedical6.45 Circulogene6.46 Clinical Genomics6.47 Cynvenio6.48 Cytolumina Technologies Corp6.49 CytoTrack6.50 Datar Cancer Genetics Limited6.51 Diagnologix LLC6.52 Diasorin S.p.A6.53 Enzo Life Sciences, Inc6.54 Epic Sciences6.55 Epigenomics AG6.56 Eurofins Scientific6.57 Exact Sciences6.58 Exosome Diagnostics6.59 Exosome Sciences6.60 Fabric Genomics6.61 Fluidigm Corp6.62 Fluxion Biosciences6.63 Foundation Medicine6.64 Freenome6.65 FUJIFILM Wako Diagnostics6.66 GeneFirst Ltd.6.67 Genetron Holdings6.68 GenomOncology6.69 GILUPI Nanomedizin6.70 Grail, Inc.6.71 Guardant Health6.72 HalioDx6.73 HansaBiomed6.74 HeiScreen6.75 Helomics6.76 Horizon Discovery6.77 HTG Molecular Diagnostics6.78 iCellate6.79 Illumina6.80 Incell Dx6.81 Inivata6.82 Integrated Diagnostics6.83 Invitae Corporation6.84 Invivogen6.85 Invivoscribe6.86 Janssen Diagnostics6.87 MDNA Life SCIENCES, Inc6.88 MDx Health6.89 Menarini Silicon Biosystems6.90 Millipore Sigma6.91 Miltenyi Biotec6.92 MIODx6.93 miR Scientific6.94 Molecular MD6.95 MyCartis6.96 Myriad Genetics/Myriad RBM6.97 NantHealth, Inc.6.98 Natera6.99 NeoGenomics6.100 New Oncology6.101 NGeneBio6.102 Novogene Bioinformatics Technology Co., Ltd.6.103 Oncocyte6.104 OncoDNA6.105 Ortho Clinical Diagnostics6.106 Oxford Nanopore Technologies6.107 Panagene6.108 Perkin Elmer6.109 Personal Genome Diagnostics6.110 Personalis6.111 Precipio6.112 PrecisionMed6.113 Promega6.114 Qiagen Gmbh6.115 Rarecells SAS6.116 RareCyte6.117 Roche Molecular Diagnostics6.118 Screencell6.119 Sense Biodetection6.120 Serametrix6.121 Siemens Healthineers6.122 Silicon Biosystems6.123 simfo GmbH6.124 Singlera Genomics Inc6.125 Singulomics6.126 SkylineDx6.127 Stratos Genomics6.128 Sysmex Inostics6.129 Tempus Labs, Inc6.130 Thermo Fisher Scientific Inc6.131 Thrive Earlier Detection6.132 Todos Medical6.133 Trovagene6.134 Variantyx6.135 Volition6.136 Vortex Biosciences

7 The Global Market for Cancer Gene Panels and Profiles7.1 Global Market Overview by Country7.2 Global Market by Cancer Type - Overview7.3 Global Market by Application - Overview7.4 Global Market by Tissue - Overview7.5 Global Market Germline & Somatic - Overview

8 Global Cancer Gene Panels & Profiles Markets - By Type of Cancer8.1 Comprehensive Panels & Profiles8.1.1 Table Comprehensive Testing - by Country8.1.2 Chart - Comprehensive Testing Growth8.2 Breast Cancer Gene Testing8.2.1 Table Breast Cancer Gene Testing - by Country8.2.2 Chart - Breast Cancer Testing Growth8.3 Colorectal Cancer Gene Testing8.3.1 Table Colorectal Cancer Gene Testing - by Country8.3.2 Chart - Colorectal Cancer Gene Testing Growth8.4 Gynecological Cancer Gene Testing8.4.1 Table Gynecological Cancer Gene Testing - by Country8.4.2 Chart - Gynecological Cancer Gene Testing Growth8.5 Blood Cancer Gene Testing8.5.1 Table Blood Cancer Gene Testing - by Country8.5.2 Chart - Blood Cancer Gene Testing Growth8.6 Prostate Cancer Gene Testing8.6.1 Table Prostate Cancer Gene Testing - by Country8.6.2 Chart - Prostate Cancer Testing Growth8.7 Lung Cancer Gene Testing8.7.1 Table Lung Cancer Gene Testing - by Country8.7.2 Chart - Lung Cancer Gene Testing Growth8.8 Other Cancer Gene Testing8.8.1 Table Other Cancer Gene Testing - by Country8.8.2 Chart - Other Cancer Gene Testing Growth

9 Global Cancer Gene Panels & Profiles Markets - By Type of Application9.1 Clinical Testing9.1.1 Table Clinical Testing - by Country9.1.2 Chart - Clinical Testing Growth9.2 Pharmaceutical Testing9.2.1 Table Pharmaceutical Testing - by Country9.2.2 Chart - Pharmaceutical Testing Growth9.3 Research Testing9.3.1 Table Research Testing - by Country9.3.2 Chart - Research Testing Growth

10 Global Cancer Gene Panels & Profiles Markets - By Tissue Type10.1 Solid Tissue10.1.1 Table Solid Tissue Testing - by Country10.1.2 Chart - Solid Tissue Testing Growth10.2 Liquid Tissue Testing10.2.1 Table Liquid Tissue Testing - by Country10.2.2 Chart - Liquid Tissue Testing Growth

11 Global Cancer Gene Testing Markets - Germline and Somatic11.1 Global Market Somatic11.1.1 Table Somatic - by Country11.1.2 Chart - Somatic Testing Growth11.2 Global Market Germline11.2.1 Table Germline - by Country11.2.2 Chart - Germline Testing Growth

12 Potential Market Opportunity Sizes12.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal12.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer12.3 Potential Market Size - Cancer Diagnosis12.4 Potential Market Size - Therapy Selection

13 Appendices

For more information about this report visit https://www.researchandmarkets.com/r/ybmn5m

Read more from the original source:
Insights on the Genomic Cancer Panel and Profiling Global Market to 2025 - GlobeNewswire

Recommendation and review posted by Bethany Smith

Global Animal Genetics Market 2021-2025 The analyst has been monitoring the animal genetics market and it is poised to grow by $ 1. 84 bn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period.

New York, July 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Animal Genetics Market 2021-2025" - https://www.reportlinker.com/p06102913/?utm_source=GNW Our report on animal genetics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing consumption of animal-derived food products and growing demand for genetic testing services to reduce livestock diseases. In addition, growing consumption of animal-derived food products is anticipated to boost the growth of the market as well.The animal genetics market analysis includes solution segment and geographic landscape.

The animal genetics market is segmented as below:By Geography North America Europe Asia ROW

By Solution Live animal Genetic testing services Genetic materials

This study identifies the growing focus on research and development in animal genomics as one of the prime reasons driving the animal genetics market growth during the next few years.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on animal genetics market covers the following areas: Animal genetics market sizing Animal genetics market forecast Animal genetics market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading animal genetics market vendors that include Animal Genetics Inc., AquaGen AS, Aviagen Inc., Cooperatie Koninklijke CRV u.a., Genetic Veterinary Sciences Inc, Genus Plc, Hendrix Genetics BV, Neogen Corp., Topigs Norsvin Holding B.V., and Zoetis Inc. Also, the animal genetics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p06102913/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Continued here:
The Global Animal Genetics Market is expected to grow by $ 1.84 bn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period -...

Recommendation and review posted by Bethany Smith

SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the 6th Annual International Conference of the Board of Genetic Counseling India to be held virtually from July 2nd-4th 2021. Dr. Chaubey has been recognized to present as an invited speaker and will discuss how optical genome mapping (OGM) is enabling a revolution in cytogenetics during a session titled Genetic Counseling in the Omics Era on Saturday July 3rd at 9:25 am IST. Dr. Akkari will present her results using OGM for the genome analysis of Acute Myelogenous Leukemia (AML), and discuss how genetic counselors can introduce OGM to patients on July 3rd at 4:10 pm IST. Bionano Genomics is a Diamond Sponsor of the conference.

This conference aims to promote education among genetic counselors, specialists, doctors, health care providers and students, about current topics in genetics, genomics and genetic counseling. The Annual International Conference of the Board of Genetic Counseling India has over 2,000 delegates from across the globe and can be accessed at bgciconference.com

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit http://www.bionanogenomics.com or http://www.lineagen.com.

Story continues

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations and Media Contact:Amy ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com

See the original post:
Bionano Genomics Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome...

Recommendation and review posted by Bethany Smith

Shahid Akhter, editor, ETHealthworld, spoke to Neeraj Gupta, Founder and CEO, Genes2me, to know more about the increased need for molecular diagnostics during the Cocvid-19 pandemic.

How has the molecular diagnostics market evolved in the last decade?The importance of Molecular Diagnostics have received significant recognition in last decade and with the emergence of Covid-19 pandemic in last 1 year, RTPCR tests have become common talking term in every house along with eruption in the Healthcare requirements. In order to cater huge requirements of RTPCR testing for Covid-19, numerous laboratories have adopted RTPCR and automated RNA Extraction platforms. Also, multiple Companies expanded their portfolio and ventured into IVD kits manufacturing as the demand increased for Made In India products.

Why there is a need for Advanced Molecular Diagnostics and Genetic testing segment?There has been increased need for Advanced Molecular Diagnostics and Genetic Tests due to increase in occurrence of Rare Genetic Disorders and new Infectious Diseases (like SARS-COV-2, Mucormycosis, etc.). Also as new strains of SARS-COV-2 are frequently being reported, importance of Advanced Genetic Testing gains significance. Recently, Genes2Me have also developed Unique Mutation Classifier assay which can rapidly differentiate 40 variants between 16 SARS-CoV-2 strains allowing quick genetic screening of large sections of population.What has been the role of technology in enhancing India's testing condition during this pandemic?With the emergence of Covid-19, the need of Molecular Diagnostics have been recognised and grown in last 1 year with spread of network of RTPCR and Automated RNA Extraction Instruments across India. It has really helped in ramping the testing for Diagnosing positive cases on time. Genes2Me is also aggressively working to leverage this massive installed base of Genetic Testing platforms. Based on our expertise in Genomics and access to latest Technologies, we have been able to develop several assays for Infectious diseases, Oncology and Reproductive Health in India. Most of these test panels have been Import dependent from other countries. Similarly, Genes2Me team is aggressively working to develop diverse range of Research and Diagnostics Solutions for Nucleic Acid testing along with Next Generation Sequencing reagents for Genome sequencing.

Genes2Me is committed to continuously deliver Innovative and scientific solutions such as much needed Unique Mutation Classifier assay for SARS-COV-2 strain and easy self-use Antigen test kits solutions which is under R&D phase, besides many other products.

***

Read more from the original source:
Emergence of new strains of SARS-COV-2, paves the way for Advanced Genetic Testing: Neeraj Gupta, Genes2me - ETHealthworld.com

Recommendation and review posted by Bethany Smith

I am nominating Lily Apfel, LVN, for the Extraordinary Healer Award. I came to know Lily in 2015 when she was diagnosed with breast cancer at the age of 35. She was a LVN working at our gastroenterology clinic. She was under my care and received comprehensive treatment including surgery, chemotherapy and radiation. During the treatment, she showed great strength and handled the tough ordeals gracefully. Our staff loved her.

Half a year later, at one of her follow-up appointments, I recruited her, and she was extremely excited and has joined us since. For the ensuing years, she has taken important roles. I am a solo provider for this community, so our staff often take multiple roles to meet the complexity of oncology care. She is our liaison and go-to person on oncology-specialty oral drugs. She is our head person on genetic testing. She handles our tumor board logistics.

There are also other attributes that make her unique. She is a great patient advocate, especially for uninsured Hispanics in our community. Lily is fluent in Spanish, and she is almost the only person these patients depend on to get their oncology care coordinated and drugs covered. She would go beyond for those patients. Lily is also very active in her own community, which is different from where she is working. It is not uncommon to hear that she does house hospice visits.

Please consider her for this Extraordinary Healer Award. Our clinic and community are very fortunate to have her.

Editors Note: This is an essay submitted by Dr. Hengbing Wang for the 2021 Extraordinary Healer Award. Click here to read more about CUREs Extraordinary Healer Award for Oncology Nursing event on April 30, 2021.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

More here:
Impacting Communities Around Her as a Patient and Nurse - Curetoday.com

Recommendation and review posted by Bethany Smith

Amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, is a rare neurological disorder that that approximately 20,000 U.S. residents are living with during any given year. And while your chances of receiving an ALS diagnosis may be relatively low, the prognosis for people with ALS is dire. According to the Centers for Disease Control and Prevention (CDC), patients with ALS typically live just two to five years after first displaying symptoms, which typically include muscle weakness or stiffness, spasms, fatigue, and difficulty swallowing, among others.

Researchers know that these symptoms arise due to the disease attacking motor neurons in the brain and spinal cord which are needed for muscle movement, but the root cause of ALS is still unfortunately unknown. Experts say that both genetic and environmental factors likely play a role. In fact, there's one genetic factor that may give you an insight into your risk level. Read on to discover the one thing 90 percent of people with ALS have have in common.

RELATED:If You Notice This in the Morning, It May Be an Early Sign of Parkinson's.

According to the ALS Association (ALSA), roughly 90 percent of patients have "sporadic ALS," a type of ALS that is not inherited through genetic mutations. In these cases, the person diagnosed is the only person in their family with the disease. The onset of their disease typically occurs later than it does in patients with a known family history of ALS.

RELATED:If You Do This at Night, It May Be an Early Sign of Parkinson's, Study Says.

The remaining 10 percent of ALS cases are considered "familial ALS" (FALS). "In these cases, more than one person in the family has ALS and sometimes family members have frontotemporal dementia as well. People with FALS often start showing symptoms at earlier ages than in sporadic ALS," writes Deborah Hartzfeld, MS, a certified genetic counselor (via the ALSA).

This statistic can spur confusion for some about one's odds of developing ALS depending on family history. While nine out of 10 people with ALS will have no known family history, you're much more likely to develop ALS if you've got a family history of the disease than if you do not.

The FALS gene mutation is most often autosomal dominant, meaning only one parent must have it in order to pass it onto their children. It also means that the affected parent has one copy of the gene with a mutation and one without, meaning they have a 50 percent chance of passing it the mutation on to their offspring.

According to the ALS Association, "typically, although not always, there will be someone in each generation with ALS and/or dementia," which appears alongside ALS in one third of cases. It is worth noting that not everyone with the genetic mutation will go on to develop symptoms of ALS.

For more health news sent directly to your inbox, sign up for our daily newsletter.

Though 90 percent of ALS cases are not the result of an inherited genetic mutation, genetic screening can help you better understand your risk if you do have a family history. This will typically require either a blood or saliva test, and can take several months to get results. The results can only be interpreted if the person in your family diagnosed with ALS is also able to participate in testing.

However, the ALSA points out that even with genetic testing, you cannot rule out the possibility of passing on familial ALS. "Not having an identified genetic mutation does not eliminate a FALS diagnosis and other family members may still be at risk for developing ALS," the organization explains. Speaking with your doctor is the first and most important step to find out your personal riskespecially if you're presenting with any possible ALS symptoms.

RELATED:This Is The Single Best Way to Predict Your Heart Attack Risk, Experts Say.

Link:
90 Percent of People With ALS Have This in Common, Experts Say - Best Life

Recommendation and review posted by Bethany Smith

New Jersey, United States,-The report titled Predictive Genetic Testing And Consumer/Wellness Genomics Market is a comprehensive document containing valuable insights into market elements such as drivers, restraints, competitive landscape, and technology development. The report offers a comprehensive analysis of key segments and future growth prospects for a better understanding of the market. The current COVID-19 pandemic has seriously altered market dynamics and the global economy. The report includes an analysis of the impact of the pandemic on the global market. It also provides current and future impact studies. The report provides a comprehensive analysis of the dynamic changes in trends and demands due to the COVID-19 pandemic. The report also contains a post-COVID scenario and prospects for future growth.

Competitive analysis includes key players and the innovations and business strategies they have implemented. The report captures the best long-term growth opportunities for the industry and includes the latest process and product developments. The report provides basic information of the companies along with their market position, history, market capitalization, and revenue. The report includes the sales figures, market growth rate and gross profit margin of each player based on regional classification and overall market position. The report provides a separate analysis of recent business strategies such as mergers, acquisitions, product launches, joint ventures, partnerships and collaborations.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketreports.com/download-sample/?rid=472815

Key Features of the Report:

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Illumina BGI Genesis Genetics Myriad Genetics 23andMe Inc Color Genomics Inc Pathway Genomics ARUP Laboratories

The report provides valuable insights into the advancement of the Predictive Genetic Testing And Consumer/Wellness Genomics market and related approaches to the Predictive Genetic Testing And Consumer/Wellness Genomics market with an analysis of each region. The report also discusses the dominant aspects of the market and examines each segment.

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

The report further studies the market segmentation based on the types of products offered in the market and their end-uses/uses.

Predictive Testing Consumer Genomics Wellness Genomics

By the application, this report covers the following segments:

Breast & Ovarian Cancer Cardiovascular screening Diabetic Screening & Monitoring Colon Cancer

Get Discount On The Purchase Of This Report @https://www.verifiedmarketreports.com/ask-for-discount/?rid=472815

Predictive Genetic Testing And Consumer/Wellness Genomics Market Report Scope

To understand the Predictive Genetic Testing And Consumer/Wellness Genomics market dynamics, the market is analyzed across major global regions and countries. Verified Market Reports provides customized specific regional and country-wise analysis of the key geographical regions as follows:

North America:USA, Canada, Mexico

Latin America:Argentina, Chile, Brazil, Peru, and Rest of Latin America

Europe:UK, Germany, Spain, Italy, and Rest of EU

Asia-Pacific:India, China, Japan, South Korea, Australia, and Rest of APAC

Middle East & Africa:Saudi Arabia, South Africa, U.A.E., and Rest of MEA

Key Elements Addressed in the Report:

Market Scenario:

The report highlights the essential features of the business sphere of the Predictive Genetic Testing And Consumer/Wellness Genomics industry. It covers development trends, factors driving the growth of the market, and segments influencing the growth of the market. It covers the product types, applications, types, deployments, and developments happening in the market.

Market Highlights:

The report provides an in-depth analysis of the market involving key elements, revenue estimations, cost analysis, import/export, production and consumption trends, CAGR, gross margin, and supply & demand patterns. The report further gives an idea about the development factors and advancement patterns of the Predictive Genetic Testing And Consumer/Wellness Genomics industry.

Analytical Tools:

The Predictive Genetic Testing And Consumer/Wellness Genomics Market is assessed through extensive primary and secondary research, which is further validated and verified by industry experts and professionals. The report examines key players operating in the market along with their market position, market share, revenue, gross margin, and business strategies. SWOT analysis and Porters Five Forces Analysis are conducted to examine and assess the market and its players. Moreover, the report also offers a feasibility study and investment return analysis to assist the readers in making strategic investment plans.

How will the report help your business grow?

? This document provides statistics on the value (in USD) and size (in units) of the Predictive Genetic Testing And Consumer/Wellness Genomics industry from 2021 to 2028.

? The report also details major competitors in the market that will have a greater impact on Predictive Genetic Testing And Consumer/Wellness Genomicss business.

? Comprehensive understanding of the fundamental trends affecting each sector despite the greatest threat, the latest technologies and opportunities that can create a global Predictive Genetic Testing And Consumer/Wellness Genomics market for both supply and demand.

? The report will help the client identify the key results of the major market players or rulers of the Predictive Genetic Testing And Consumer/Wellness Genomics sector.

For More Information or Query or Customization Before Buying, Visit @https://www.verifiedmarketreports.com/product/predictive-genetic-testing-and-consumer-wellness-genomics-market-size-and-forecast/

Visualize Predictive Genetic Testing And Consumer/Wellness Genomics Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Predictive Genetic Testing And Consumer/Wellness Genomics Market using VMI @https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketreports.com

Website: https://www.verifiedmarketreports.com/

Go here to see the original:
Predictive Genetic Testing And Consumer/Wellness Genomics Market Size and Growth 2021-2027 | Top Manufacturers Illumina, BGI, Genesis Genetics,...

Recommendation and review posted by Bethany Smith

Genetic testing, or more specifically pharmacogenomics, plays an important role by enabling healthcare providers to more accurately predict which treatments will work well, as well as which drugs may lead to unwanted side effects.

In the case of cancer treatments, it is also possible to look at the genome of the tumour itself to see which therapies are most likely to be effective. The Clinical Pharmacogenetics Implementation Consortium (CPIC) is an international group dedicated to facilitating the use of pharmacogenomic testing for patient care. One such example of this is dihydropyrimidine dehydrogenase (DPD) enzyme deficiency screening, by way of DPYD gene testing. Yourgene Health are proud to be supporting the international roll out of this screening to the benefit of millions of patients undergoing treatment for cancer.

Fluoropyrimidines such as 5-Fluorouracil (5-FU) and its prodrugs capecitabine and tegafur are chemotherapy agents widely used in the treatment of patients with gastrointestinal (GI), head/neck, breast, and other forms of solid tumour cancer. Only a fraction of a fluoropyrimidine drug is transformed into active cytotoxic agents. The dihydropyrimidine dehydrogenase (DPD) enzyme is necessary to catabolise most of these agents to inactive products, thus limiting the circulating levels of fluoropyrimidines. When DPD enzyme activity is deficient, patients treated with standard dosing of fluoropyrimidines are at significantly increased risk of severe toxicities or even death. The DPYD gene encodes for the synthesis of the DPD enzyme. DPD enzyme deficiency is strongly correlated with certain variants in the DPYD gene.

Fluoropyrimidines-based chemotherapy is used to treat over two million patients every year across the world. 3-8% of individuals are believed to be carriers of one or more known risk variants in DPYD gene. Carriers of a causative variant are at up to an 88% risk of severe toxicity if treated with a standard dose. DPYD testing helps identify those individuals who are at increased risk of these toxic side effects. These patients can be offered alternative therapies or lower treatment doses. The CPIC has issued guidance on dosage modifications recommended for a select number of genotypes and their associated activity score. Pre-emptive genotyping of all patients for these specific variants has proven highly precise in predicting an adverse drug response, with a specificity of ~95%.

Late last year NHS England announced that all at-risk cancer patients (approximately 38,000 each year) will now routinely be tested for DPYD variants. The Elucigene DPYD assay is already in use across multiple laboratories in several English Genomic Laboratory Hubs, including Liverpool and Cambridge.

The assay is also being used to provide nation-wide testing in Wales following a successful pilot programme with All Wales Medical Genomics Service (AWMGS), and for Scotland in within the Genetic Consortium Laboratories. In Wales alone, the test is used to screen approximately 200 patients each month. If the screen positive rate of 6% identified in the pilot continues, we anticipate 144 cancer patients will be prevented from having toxic chemotherapy reactions over the next year.

Please note: This is a commercial profile

2019. This work is licensed under aCC BY 4.0 license.

Editor's Recommended Articles

See the original post:
DPYD genotyping to improve patients' therapy response - Open Access Government

Recommendation and review posted by Bethany Smith

This piece originally appeared on the Good Notes blog.

Virtual health care is here to stay. Many believe the era of telehealth was launched by the coronavirus pandemic. It wasnt, but the health crisis certainly accelerated it. Prior to the pandemic, 2% of University of Utah Health providers had seen patients virtuallynow, 90% have. From March 2020 to March 2021, our providers held 400,000 virtual telehealth sessions. That amounts to between 6,000 and 8,000 sessions a week.

Telehealth will continue to evolve. It already involves more than live transmission of a patients face onto a providers device while the patient describes his or her state of health and asks questions. As diagnostics continue to improve, patients will be able to do more within their own homes. Wearable medical devices are increasingly integrated with remote care delivery. Remote labs continue to emerge, changing how patients monitor their health. Think of swabs that patients collect in the comfort of home and drop into a mailbox for analysis. This exists for genetic testing companies like 23andMe. We did it with COVID-19 tests. Coronavirus testing advanced quite rapidly so that someone at home could do a self-swab and send it back to a central lab.

For more complex lab diagnostics, imagine the day when a lab technician comes to your home to collect samples for testing or perform imaging tests like an X-ray. The idea is to flip the supply chain upside down: Instead of the patient coming to the hospital, lab or imaging center, why not the hospital, lab, or imaging center going to the patient?

The premise of all these things is making health care more convenient, easier to access, and ultra-consumer-centered. Delivery in the home, or wherever it may be convenient for the patient, is a rapidly expanding trend. Video visits are just one component of it. Certain visits still need hands-on evaluation, often with a video component. From my perspective as an orthopaedist, we had to develop a structure for telehealth sessions to be effective. We now have a short video we send to patients ahead of time that tells them the multiple steps they should take before treatment. For a new patient appointment, I need the patient to make certain videos and take certain photographs of themselves to send in, before I see them virtually. My colleagues and I intend to streamline virtual visits even more because its incredibly cost-effective and time-effective for the patient.

Telehealth also means better access to care and treatment at U of U Health for our patient base geographically spread across the Mountain West and beyond. We have one of the most rural populations of a major academic medical center anywhere in the country. Virtual care gives us a chance to reach out, talk to, and evaluate patients across broad geography without them needing to leave their homes or burn carbon fuels. It gets us even closer to University of Utah Healths goal of providing our regional population with access to world-class patient-centered care.

With telehealths initial success and great potential, its still not for everyonenor effective for every condition. Many patients remain skeptical about virtual visits, thinking their physician may not get an accurate picture or full understanding of their health issue. There are also patients who just find comfort and reassurance from in-person conversations. We need to give patients choice. As long as it is clinically appropriate, telehealth works wellespecially when we match the right circumstances to a patients preference.

Our data shows that whats wanted is as varied as our patient populations. A core group of more digitally literate patients quickly recognized the benefits of virtual care. Most of these patients connect to us with their smartphones. They are motivated to learn quickly because digital technology connects with their physicianand helps them bring in family members from dispersed locations to participate in health care visits. Yet theres a huge swath of our patient population that hasnt had enough digital experience to be comfortable talking device to device.

The telehealth option is increasingly widespread. Its not just at U of U Health, an academic health organization with state-of-the-art digital equipment, where the reconfigured world of patient care is underway. Traditional health care business models of all sizes are expanding home-based clinical care. Coalitions have formed among health care groups to support policy changes that designate the home as a site of clinical service.

With vaccinations and the number of COVID cases falling during the last couple of months, theres been an appropriate decrease in virtual care within our system. But it has not returned to pre-COVID levels. It is here to stay. So our mission in approaching the new normal is to pivot and be especially strategic about virtual care to ensure that we use it to meet the needs of our patients. Whenever possible, we also want to offer the deep resources of our academic tertiary health care system. We need to maintain exceptional value with high standards of quality and experience for patients and providers.

More:
Here to stay: The era of telehealth | @theU - @theU

Recommendation and review posted by Bethany Smith

The Latest Direct to consumer Genetic Testing Market report helps to identify the growth factors and business opportunities for the new entrants in the Global Direct to consumer Genetic Testing industry with a detailed study of Market Dynamics and technological innovations and trends of the Global Direct to consumer Genetic Testing Market. The report covers all leading vendors operating in the market and the small vendors which are trying to expand their business at a large scale across the globe. That report presents strategic analysis and ideas for new entrants using a historic data study. The study report offers a comprehensive analysis of market share in terms of percentage share, gross premium, and revenue of major players functioning in the industry of the Global market. Thus, the report provides an estimation of the market size, revenue, sales analysis, and opportunities based on the past data for current and future market status.

This research report offers PESTEL analysis, Porters Five Force Analysis, and Ecosystem analysis of the Global Direct to consumer Genetic Testing Market. Furthermore, the research report covers all the major countries and regions which have a good market scale of different vendors in those regions. Also, the report forecasts the market size of the Global Direct to consumer Genetic Testing Market in Compound Annual Growth Rate in terms of revenue during the forecast period. The research report also offers in-depth analysis about the Agreements, collaboration, and partnership among different vendors across the globe to expand the business of the Global Direct to consumer Genetic Testing Market.

Request for a sample copy of the report to get extensive insights into Direct to consumer Genetic Testing market and Get Upto 30% Discount at https://www.in4research.com/sample-request/48195

Top listed Players for Global Direct to consumer Genetic Testing Market are:

How has the competitive landscape of this industry been categorized?

Direct to consumer Genetic Testing Market Segmentation by Type, Application, and Region as follows:

By Type:

By Application:

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue, and market share and growth rate of Direct to consumer Genetic Testing in the following regions:

For more Customization, Connect with us at https://www.in4research.com/customization/48195

Valuable Points Covered in Direct to consumer Genetic Testing Research Study are:

Reasons to Access Direct to consumer Genetic Testing Market Report:

Buy Full Research Report at https://www.in4research.com/buy-now/48195

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan

Email: contactus@in4research.com

Phone: +1 (407) 768-2028

Original post:
Direct to consumer Genetic Testing Market Research Insight 2021 Complete Overview & Qualitative Analysis by Major Companiess like 23andMe,...

Recommendation and review posted by Bethany Smith